AUBURN, Wash., Dec. 9, 2022 /PRNewswire/ -- Syntrix Pharmaceuticals today announced results from a single-arm, open-label Phase 1 trial of single-agent SX-682, an investigational CXCR1/2 inhibitor, in patients with any-risk myelodysplastic syndromes (MDS) in whom front-line hypomethylating-agent (HMA) had failed, a high unmet need population. Results support the clinical activity of SX-682. The data will be presented by David Sallman, MD of the H. Lee Moffitt Cancer Center and Research Institute, an investigator for the clinical trial, during an afternoon oral session on December 12, 2022 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract #855).
AUBURN, Wash., Oct. 27, 2020 /PRNewswire/ -- Syntrix Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class product candidates focused on emerging immune control mechanisms in oncology indications, announced today it completed initial SX-682 dosing in Phase 1/2 trials in myelodysplastic syndromes (MDS) and metastatic melanoma. The drug was well tolerated and absorbed with excellent dose-proportional drug levels in blood. The trials are being conducted at the Moffitt Cancer Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, Mayo Clinic and the University of Rochester.
Syntrix Pharmaceuticals announces the discovery that desmetramadol is a G-protein biased opioid receptor agonist. The results, published in Frontiers in Pharmacology show that desmetramadol, the active metabolite of tramadol, is as effective as morphine, oxycodone and fentanyl in eliciting G protein coupling at the human ? opioid receptor (MOR) involved in pain relief, but surprisingly, supra-therapeutic concentrations typical of overdose spare human MOR-mediated barrestin2 recruitment, the signaling pathway of the receptor thought to mediate lethal opioid-induced respiratory depression.
Syntrix Pharmaceuticals, Inc., a leading innovator of new pain therapy for the broad multi-billion dollar global pain market, today announced that Syntrix's President and CEO, John Zebala, MD, PhD, will present an overview of desmetramadol and positive first-in-man trial results at the 2019 Pain Management SUMMIT. The presentation will take place on Wednesday, November 20th at 10:00 AM EST at The Inn at Penn in Philadelphia.
Syntrix Pharmaceuticals today announced the publication of positive results from two consecutive randomized and double-blind controlled trials that compared desmetramadol to placebo and tramadol. The results, published in The Journal of Pain showed that desmetramadol has the same analgesic and side effect profile of tramadol, but without tramadol's known metabolic liabilities that hamper its efficacy and safety
Syntrix Wins $3.4M NIH Grant to Conduct Phase 1/2 Trial of SX-682 in Myelodysplastic Syndrome